140 related articles for article (PubMed ID: 9448589)
21. Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.
Jarrell JA; Baker MC; Perugino CA; Liu H; Bloom MS; Maehara T; Wong HH; Lanz TV; Adamska JZ; Kongpachith S; Sokolove J; Stone JH; Pillai SS; Robinson WH
J Allergy Clin Immunol; 2022 Jan; 149(1):358-368. PubMed ID: 33974929
[TBL] [Abstract][Full Text] [Related]
22. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
23. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus.
Jolly M; Francis S; Aggarwal R; Mikolaitis RA; Niewold TB; Chubinskaya S; Block JA; Scanzello C; Sequeira W
Lupus; 2014 Aug; 23(9):881-8. PubMed ID: 24786785
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
[TBL] [Abstract][Full Text] [Related]
25. Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus.
Hsieh SC; Tsai CY; Sun KH; Tsai YY; Tsai ST; Han SH; Yu HS; Yu CL
Br J Rheumatol; 1995 Feb; 34(2):107-12. PubMed ID: 7704455
[TBL] [Abstract][Full Text] [Related]
26. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.
Park YB; Lee SK; Kim DS; Lee J; Lee CH; Song CH
Clin Exp Rheumatol; 1998; 16(3):283-8. PubMed ID: 9631750
[TBL] [Abstract][Full Text] [Related]
27. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
28. Plasma interleukin-1alpha, interleukin-1beta and interleukin-1 receptor antagonist levels in pre-eclampsia.
Kimya Y; Akdiş C; Cengiz C; Ozan H; Tatlikazan S; Uncu G; Sengül F
Eur J Obstet Gynecol Reprod Biol; 1997 May; 73(1):17-21. PubMed ID: 9175684
[TBL] [Abstract][Full Text] [Related]
29. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE.
Andersen LS; Petersen J; Svenson M; Bendtzen K
Autoimmunity; 1999; 30(4):235-42. PubMed ID: 10524499
[TBL] [Abstract][Full Text] [Related]
30. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
Ho A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
[TBL] [Abstract][Full Text] [Related]
31. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
Mok CC; Ho LY; Leung HW; Wong LG
Transl Res; 2010 Dec; 156(6):320-5. PubMed ID: 21078493
[TBL] [Abstract][Full Text] [Related]
32. Increased urinary interleukin 22 binding protein levels correlate with lupus nephritis activity.
Yang X; Gao Y; Wang H; Zhao X; Gong X; Wang Q; Zhang X
J Rheumatol; 2014 Sep; 41(9):1793-800. PubMed ID: 25086075
[TBL] [Abstract][Full Text] [Related]
33. Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome.
van Bommel EF; Hesse CJ; Jutte NH; Zietse R; Bruining HA; Weimar W
Ren Fail; 1997 May; 19(3):443-54. PubMed ID: 9154661
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.
Atta MS; Lim KL; Ala'deen DA; Powell RJ; Todd I
Ann Rheum Dis; 1995 Feb; 54(2):117-24. PubMed ID: 7702398
[TBL] [Abstract][Full Text] [Related]
35. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.
Thanadetsuntorn C; Ngamjanyaporn P; Setthaudom C; Hodge K; Saengpiya N; Pisitkun P
Sci Rep; 2018 Feb; 8(1):2620. PubMed ID: 29422675
[TBL] [Abstract][Full Text] [Related]
36. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients.
He D; Liu M; Liu B
Tohoku J Exp Med; 2018 Apr; 244(4):263-270. PubMed ID: 29576585
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus.
Cigni A; Pileri PV; Faedda R; Gallo P; Sini A; Satta AE; Marras R; Carta E; Argiolas D; Rum I; Masala A
J Investig Med; 2014 Jun; 62(5):825-9. PubMed ID: 24987977
[TBL] [Abstract][Full Text] [Related]
39. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies.
Narayanan K; Marwaha V; Shanmuganandan K; Shankar S
Med J Armed Forces India; 2010 Apr; 66(2):102-7. PubMed ID: 27365721
[TBL] [Abstract][Full Text] [Related]
40. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus.
Firooz N; Albert DA; Wallace DJ; Ishimori M; Berel D; Weisman MH
Lupus; 2011 May; 20(6):588-97. PubMed ID: 21436216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
